SAREPTA THERAPEUTICS ($NASDAQ:SRPT) reported total revenue of USD 261.2 million for the second quarter of FY2023 which ended on June 30 2023, a year-on-year increase of 11.9%. Net income for the period was USD -23.9 million, significantly better than the same quarter in the previous year when it was -231.5 million. Results were announced on August 2 2023.
Analysis – Sarepta Therapeutics Stock Intrinsic Value
GoodWhale provides an in-depth look into the financials of SAREPTA THERAPEUTICS, giving investors the opportunity to analyze the company’s value and make informed decisions. Using GoodWhale’s proprietary Valuation Line, the fair value of SAREPTA THERAPEUTICS shares is estimated to be around $123.3. Despite this calculated fair value, SAREPTA THERAPEUTICS stock is currently traded at $105.2, a price 14.7% undervalued from the calculated fair value. This discrepancy presents a good opportunity for potential investors to acquire the stock at a reduced price, making it an attractive investment option. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Sarepta Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sarepta Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sarepta Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Sarepta Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The company is headquartered in Cambridge, Massachusetts and was founded in 1980. Sarepta Therapeutics Inc has four main competitors: Genor Biopharma Holdings Ltd, Impel Pharmaceuticals Inc, Entera Bio Ltd, and PTC Therapeutics Inc. These companies are all focused on the development of treatments for DMD and other rare diseases.
– Genor Biopharma Holdings Ltd ($SEHK:06998)
Genor Biopharma Holdings Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative drugs for the treatment of cancer. The company has a market cap of 949.11M as of 2022 and a ROE of -23.99%. The company’s products are designed to target specific genetic mutations that are known to drive the growth and progression of cancer.
– Impel Pharmaceuticals Inc ($NASDAQ:IMPL)
Impel Pharmaceuticals Inc is a pharmaceutical company with a market cap of 94.72M as of 2022. The company has a Return on Equity of -359.89%. Impel Pharmaceuticals Inc is a company that focuses on the development and commercialization of drugs for the treatment of central nervous system disorders.
Entera Bio Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of oral therapeutics for serious unmet medical needs. The company’s lead product candidate is EB614, an oral biologic that is in clinical development for the treatment of osteoporosis, inflammatory bowel disease, and other immune-mediated diseases. Entera Bio Ltd has a market cap of 24.06M as of 2022, a Return on Equity of -48.6%. The company’s focus on the development and commercialization of oral therapeutics makes it a unique player in the biopharmaceutical market. However, its negative ROE indicates that it is not a profitable company at this time.
Sarepta Therapeutics, a biopharmaceutical company, recently reported its financial results for the second quarter of FY2023. Total revenue was 261.2 million, up 11.9% year over year. Net income was -23.9 million, a substantial improvement from -231.5 million reported the previous year.
Investors should note the strong financial performance and growth in revenue, pointing to a promising future for the company. Furthermore, this income figure shows that Sarepta is continuing to make progress in reducing its losses since last year, which is a positive sign for the company’s recent investments and initiatives.